{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:51:44Z","timestamp":1758127904840,"version":"3.41.2"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"DOI":"10.7759\/cureus.88164","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T14:47:33Z","timestamp":1752763653000},"source":"Crossref","is-referenced-by-count":1,"title":["Co-occurrence of Congenital Osteogenesis Imperfecta and Maternal Antiphospholipid Syndrome: A Novel Case Report"],"prefix":"10.7759","author":[{"given":"Mouna","family":"Zouine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Sekkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houda","family":"Moustaide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Benkirane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Oulmaati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk FS","year":"2014","unstructured":"Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014, 164A:1470-81. 10.1002\/ajmg.a.36545","journal-title":"Am J Med Genet A"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead562","article-title":"Parental autoimmunity and offspring risks of rheumatic diseases: a nationwide population-based study","volume":"63","author":"Shao YJ","year":"2024","unstructured":"Shao YJ, Chen YM. Parental autoimmunity and offspring risks of rheumatic diseases: a nationwide population-based study. Rheumatology (Oxford). 2024, 63:2189-98. 10.1093\/rheumatology\/kead562","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2010.08.002","article-title":"Characterising and treating osteogenesis imperfecta","volume":"86","author":"Bishop N","year":"2010","unstructured":"Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev. 2010, 86:743-6. 10.1016\/j.earlhumdev.2010.08.002","journal-title":"Early Hum Dev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00096-1","article-title":"The outcomes of children born to mothers with autoimmune rheumatic diseases","volume":"6","author":"Andreoli L","year":"2024","unstructured":"Andreoli L, Andersen J, Avcin T, et al.. The outcomes of children born to mothers with autoimmune rheumatic diseases. Lancet Rheumatol. 2024, 6:e573-86. 10.1016\/S2665-9913(24)00096-1","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2012.01.003","article-title":"Pregnancy and antiphospholipid syndrome. (Article in French)","volume":"33","author":"Costedoat-Chalumeau N","year":"2012","unstructured":"Costedoat-Chalumeau N, Guettrot-Imbert G, Leguern V, et al.. Pregnancy and antiphospholipid syndrome. (Article in French). Rev Med Interne. 2012, 33:209-16. 10.1016\/j.revmed.2012.01.003","journal-title":"Rev Med Interne"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4161\/chim.2.3.17589","article-title":"Can maternal microchimeric cells influence the fetal response toward self antigens?","volume":"2","author":"Leveque L","year":"2011","unstructured":"Leveque L, Khosrotehrani K. Can maternal microchimeric cells influence the fetal response toward self antigens?. Chimerism. 2011, 2:71-7. 10.4161\/chim.2.3.17589","journal-title":"Chimerism"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2016.1151870","article-title":"Health outcomes of neonates with osteogenesis imperfecta: a cross-sectional study","volume":"29","author":"Yimgang DP","year":"2016","unstructured":"Yimgang DP, Brizola E, Shapiro JR. Health outcomes of neonates with osteogenesis imperfecta: a cross-sectional study. J Matern Fetal Neonatal Med. 2016, 29:3889-93. 10.3109\/14767058.2016.1151870","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.ANC.0000311013.71510.41","article-title":"Osteogenesis imperfecta in the neonate","volume":"8","author":"Hackley L","year":"2008","unstructured":"Hackley L, Merritt L. Osteogenesis imperfecta in the neonate. Adv Neonatal Care. 2008, 8:21-30. 10.1097\/01.ANC.0000311013.71510.41","journal-title":"Adv Neonatal Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000536324","article-title":"Association of antenatal evaluations with postmortem and genetic findings in the series of fetal osteogenesis imperfecta","volume":"51","author":"Senturk L","year":"2024","unstructured":"Senturk L, Gulec C, Sarac Sivrikoz T, et al.. Association of antenatal evaluations with postmortem and genetic findings in the series of fetal osteogenesis imperfecta. Fetal Diagn Ther. 2024, 51:285-99. 10.1159\/000536324","journal-title":"Fetal Diagn Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.06.066","article-title":"Short-term safety assessment in the use of intravenous zoledronic acid in children","volume":"145","author":"H\u00f6gler W","year":"2004","unstructured":"H\u00f6gler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004, 145:701-4. 10.1016\/j.jpeds.2004.06.066","journal-title":"J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George S","year":"2015","unstructured":"George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. J Clin Endocrinol Metab. 2015, 100:4163-71. 10.1210\/jc.2015-2680","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2015-0351","article-title":"Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children","volume":"29","author":"Kumar C","year":"2016","unstructured":"Kumar C, Panigrahi I, Somasekhara Aradhya A, Meena BL, Khandelwal N. Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children. J Pediatr Endocrinol Metab. 2016, 29:947-52. 10.1515\/jpem-2015-0351","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384669-co-occurrence-of-congenital-osteogenesis-imperfecta-and-maternal-antiphospholipid-syndrome-a-novel-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T14:47:34Z","timestamp":1752763654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384669-co-occurrence-of-congenital-osteogenesis-imperfecta-and-maternal-antiphospholipid-syndrome-a-novel-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.88164","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}